https://doi.org/10.31288/oftalmolzh201542834

Amino acids in the vitreous and intravitreal fluid in rhegmatogenous retinal detachment patients with different proliferative vitreoretinopathy grades

G.V. Levitskaya, Cand. Sc. (Med)

Filatov Eye Disease and Tissue Therapy Institute, Odessa

E-mail: g.levytskaya@mail.ru

Background:Proliferative vitreoretinopathy (PVR) is known to worsen the treatment prognosis of rhegmatogenous retinal detachment (RRD) and to result in irreversible loss of vision due to apoptotic or necrotic process in retinal neurons. Some studies have tried to examine the role of amino acids (first of all, neurotransmitters) in the development of proliferative vitreoretinopathy (PVR). Glutamate is known to cause migration and proliferation of RPE and/or glial cells. Based on this fact, it has been hypothesized that antagonists of glutamate may prevent or reduce the intensity of these processes. Additionally, it has been proved that elevated vitreous glutamate levels in proliferative diabetic retinopathy are potentially toxic to retinal ganglion cells, and that elevated vitreous levels of gamma-aminobutyric acid and glutamate promote the development of vasoproliferative processes. In general, little is still known about the role of immune acids and that of the imbalance in their levels in the pathogenesis of retinal pathology, and the importance of the issue of PVR complications is of no doubt.

Purpose: To investigate the features of the distribution of amino acids in the vitreous and intravitreal fluid in patients with RRD with different PVR grades.

Materials and Methods: Eighty-eight patients (88 eyes) were ofthalmologically examined and underwent surgery for RRD. Gas-liquid chromatography was utilized to determine the levels of 15 amino acids in vitreous and intravitreal fluid samples obtained at the time of vitrectomy and fluid-gas exchange to provide tamponade, respectively. Data were analyzed taking into account the PVR grade (grades A, B and C in 11, 64 and 13 patients, respectively).

Results: In RRD patients, the levels of amino acids under study in the vitreous and, especially, in intravitreal fluid increased significantly with the increase in PVR grade to grade B. If the PVR continued to progress to grade C, a tendency to decrease in the neurotransmitter levels was observed, but they remained statistically significantly higher than those in grade A. Significant correlations were revealed between PVR grade and amino acid levels in intravitreal fluid, and, in most cases, in the vitreous. Further progression of the proliferative process was accompanied by a higher increase in the levels of excitatory amino acids (aspartate and glutamic acid), than that of the inhibitory one (glycine).

Conclusion: The data presented provide evidence for the role of elevated amino acid (first of all, neurotransmitter) levels in the development of proliferative processes in RRD. The imbalance found in the levels of excitatory and inhibitory neurotransmitters (aspartate and glutamic acid vs. glycine) results in the excitotoxic effect, and creates pathochemical preconditions for retinal degeneration.

Keywords: rhegmatogenous retinal detachment, proliferative vitreoretinopathy, amino acids, neurotransmitters, intravitreal fluid, vitreous. 

References

1. Medzhidova SR. [Posttraumatic proliferative vitreoretinopathy: Literature Review].Oftalmologiya. 2012;10(3):113-20. Russian.

2. Zapuskalov IV, Krivosheina OI. [Current concept of the pathogenesis of proliferative vitreoretinopathy]. In: [Proceeding of the Conference on New Technologies for the Treatment of Vitreoretinal Pathology]; 2006 Mar 23-24; Moscow (Russia): Eye Microsurgery Federal State Institution; 2006. p.72-76. Russian.

3. Dreyer EB, inventor; Allergan Sales, Inc., assignee. Calcium blockers to treat proliferative vitreoretinopathy. United States patent US 20050192322 A1. 2005 Sept 1.

4. Ambati J, Chalam KV, Chawla DK et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 1997; 115 (9):1161–6.
Crossref   Pubmed

5. Abdullaieva EA, Saidova LKh, Zeinalova IF. [Clinical significance of antiangiogenic therapy of a subretinal neovascular membrane in complicated myopia]. Oftalmologiya. 2013;11(1):57-63. Russian.

6. Levitskaya GV. [Potential to minimize surgery for rhegmatogenous retinal detachment]. In: [Proceeding of the 9th Conference on New Technologies for the Treatment of Vitreoretinal Pathology]; 2011 Mar 10-11; Moscow (Russia): Eye Microsurgery Federal State Institution; 2011. p.123-125. Russian.

7. Levitskaya GV. [Amino acid spectrum in vitreous body and vitreous content in patients with retinal detachment]. Rus Det Oft. 2014;1:16-20. Russian.

8. Glantz SA. Primer of Biostatistics. 4th ed. [Transl. from English]. Moscow: Praktika;1998. 459 p. Russian.